Over the last 12 months, two Ardent Health, Inc. insiders picked up shares on the open market, about $186,000 in total, and none of them sold.
The largest purchase came from DeMichiei Robert (Director), about $98,000. Notably, at least one C-suite executive was among the buyers.
No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters. Big money check: 139 institutions held ARDT as of Q2 2026, and more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Jun 8, 2026 | DeMichiei Robert | Director | Buy | 11,260 | $8.73 | $98K | SEC |
| Jun 8, 2026 | LUMSDAINE ALFRED | CFO | Buy | 10,000 | $8.81 | $88K | SEC |
| Nov 13, 2024 | Webb Robert Thomas | Director | Buy | 10,000 | $16.49 | $165K | SEC |
| Nov 13, 2024 | Webb Robert Thomas | Director | Buy | 10,000 | $17.47 | $175K | SEC |
In the last 12 months Ardent Health, Inc. insiders made open-market purchases worth about $186,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in ARDT was filed on 2026-06-08.
139 investment managers reported holding ARDT in SEC Form 13F filings for Q2 2026.
No congressional trades in ARDT were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).